PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin
PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin (External Link)
Update on PharmAust Canine Cancer Trials
Update on PharmAust Canine Cancer Trials
PharmAust’s MPL trials show doubled life expectancy for dogs with cancer
PharmAust’s MPL trials show doubled life expectancy for dogs with cancer (External Link)
PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials
PharmAust (ASX:PAA) sees “significant progress” in dog cancer trials (External Link)
Top 20 Shareholders
Top_Holders_Report (4)
PharmAust opens door to billion-dollar markets, following MPL trial successes
PharmAust opens door to billion-dollar markets, following MPL trial successes (External Link)
Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success
Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success (External Link)
JP Equity Research Report
JP Equity Research Note – July 2022
Appendix 4C and Quarterly Update
Appendix 4C and Quarterly Update – June 2022
PharmAust subsidiary Epichem lands pilot deal with Shell Australia to convert waste plastic to products
Learn More (External Link)